# SOR-C13

| | |
|---|---|
| **Cat. No.:** | HY-P1651 |
| **CAS No.:** | 1187852-48-7 |
| **Molecular Formula:** | $C_{72}H_{116}N_{20}O_{19}$ |
| **Molecular Weight:** | 1565.81 |
| **Sequence Shortening:** | KEFLHPSKVDLPR |
| **Target:** | TRP Channel |
| **Pathway:** | Membrane Transporter/Ion Channel; Neuronal Signaling |
| **Storage:** | Please store the product under the recommended conditions in the Certificate of Analysis. |

## BIOLOGICAL ACTIVITY

| | |
|---|---|
| **Description** | SOR-C13, a carboxy-terminal truncated peptide, is a high-affinity TRPV6 antagonist with an $IC_{50}$ value of 14 nM. TRPV6 is a non-voltage gated calcium channel that is associated with malignancy and poor prognosis in breast cancer. SOR-C13 has anticancer activity[1]. |
| **$IC_{50}$ & Target** | TRPV6<br>14 nM ($IC_{50}$) |
| **In Vivo** | SOR-C13 (i.p.; 400,600, 800 mg/kg; daily; on days 1 to 12) can effectively inhibit the growth of tumor in female NOD/SCID mice with SKOV-3 cell[2].<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

| | |
|---|---|
| Animal Model: | Female NOD/SCID mice with SKOV-3 cell[2] |
| Dosage: | 400,600, 800 mg/kg |
| Administration: | IP; daily; on days 1 to 12 |
| Result: | Effectively inhibited the growth of tumor. |

## REFERENCES

[1]. S Fu , et al. Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2017 Jun;35(3):397.

[2]. Hui Xue, et al. Inhibition of Transient Receptor Potential Vanilloid 6 channel, elevated in human ovarian cancers, reduces tumour growth in a xenograft model. J Cancer. 2018 Aug 6;9(17):3196-3207.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA